Better Health for All

Castle Biosciences' core business is entirely focused on developing and commercializing diagnostic tests for various cancers and mental health conditions, with the explicit mission of improving health through innovative tests that guide patient care.

The company's entire product portfolio, including tests for melanoma, squamous cell carcinoma, uveal melanoma, Barrett's esophagus, and mental health conditions, aims to provide personalized genomic information to improve treatment decisions and patient outcomes, with no evidence of negative health impacts. Over 300,000 test reports have been delivered since 2008, supported by over 150 peer-reviewed publications demonstrating clinical validity and utility. The DecisionDx-Melanoma test, for example, has shown 100% recurrence-free survival in low-risk patients who avoided sentinel lymph node biopsy, reducing unnecessary procedures and associated complications. The company performs its tests in CAP-accredited and CLIA-certified laboratories, and maintains state licenses, indicating strong safety and quality controls. The company offers a comprehensive patient assistance program and works with all insurance providers, but specific quantitative data on the percentage of patients reached or the pricing relative to production cost is not provided. The company's DEI efforts include 50% women on its board of directors, 63% women in the workforce, and 39% women in executive positions as of December 31, 2023, and it has an Affirmative Action Program. The company has a strong commitment to protecting confidential, proprietary, and personal information, complying with HIPAA and other privacy laws. While the company has active R&D programs for new tests, specific percentages of R&D budget allocated to health improvement are not disclosed. The company's vendor code of conduct outlines expectations for environmental responsibility, but no specific data on health externalities from its own operations is provided. The company also offers competitive benefits and professional development opportunities for its employees, with an 86% employee engagement score in 2023, above the healthcare benchmark average of 75%. The company's IDgenetix test guides personalized mental health medication selection and management. The company employs a direct sales and marketing strategy and an experienced medical affairs group to educate clinicians on the clinical and economic benefits of its products. Clinical trials are conducted in accordance with FDA's IDE regulations and good clinical practice regulations for IRB approval and informed consent.

Fair Money & Economic Opportunity

Castle Biosciences, Inc. is a medical diagnostics company, not a financial institution. The company's core business involves providing genomic information for cancer treatment decisions, not offering lending, insurance, or other financial services to consumers.

Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions based on their lending practices, fee structures, financial inclusion initiatives, and customer financial data management, are not applicable. The provided articles discuss the company's commitment to patient access to testing, including working with various insurance providers (Medicare, Medicaid, VA) and offering patient assistance programs, but these relate to healthcare access, not financial products or services as defined by the rubric. No specific, concrete data points relevant to the quantitative thresholds of these financial KPIs were found.

Honest & Fair Business

Castle Biosciences has a whistleblower policy that includes a toll-free compliance hotline, an online web form, and an 'Open Door Policy' for reporting suspected violations.

The company explicitly states it will not tolerate retaliation against those who report misconduct, and anonymous reporting is permitted. A Compliance Officer and the Audit Committee oversee the process, tracking complaints and preparing quarterly summaries. Seven of the eight board members are independent. The company has an anti-corruption policy with a zero-tolerance stance on corruption, prohibiting improper payments to government officials, and stating compliance with laws like the FCPA. All employees completed Compliance, Fraud, Waste & Abuse training in 2022.

No War, No Weapons

Castle Biosciences' core business is dermatologic cancer diagnostics, with no evidence of revenue from arms or defense contracts, dual-use technology development, or peacebuilding investments.

The company and its vendors are expected to comply with U.S. embargoes, including those against Cuba, Iran, North Korea, Sudan, and Syria, and adhere to U.S. Export Controls, which restrict exports and re-exports of goods, software, and technology. Human-rights due diligence is conducted annually through comprehensive compliance and ethics training for employees, and the Environmental Policy Statement is reviewed periodically by the Chief Operating Officer. The company's Code of Business Conduct and Ethics outlines a commitment to maintaining high standards of ethics and responsible business practices, and vendors are expected to adhere to this Code.

Respect for Cultures & Communities

The provided articles, including the company's ESG reports and corporate responsibility program summaries, do not contain specific quantitative data or explicit mentions for any of the KPIs related to Respect for Cultures & Communities.

For each relevant metric, the articles explicitly state that no data is provided, no mention is made, or the information is not directly applicable to the specific KPI definition. Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

Castle Biosciences has not experienced any reportable attacks or breaches under SEC Cybersecurity Disclosure rules as of September 30, 2024.

A formal Cyber Incident Response Plan is in place to prepare for, respond to, and recover from cyber incidents, covering all employees, non-employees, business partners, and devices housing company information. The company became a member of Health-ISAC in 2024. All employees (100%) received data security and privacy training in both 2023 and 2024. The company mentions having a vulnerability management policy and conducting penetration tests. Its privacy policy, effective June 25, 2019, and last modified October 12, 2019, states that it collects only necessary data and complies with HIPAA and other laws.

Zero Waste & Sustainable Products

Castle Biosciences has implemented employee-driven recycling efforts at its Friendswood headquarters to collect aluminum and cardboard.

The company engages a third-party vendor for hazardous waste treatment and disposal and is noted as a 'minimal volume generator.' No regulatory warnings related to waste disposal were noted over 2020-2022. Additionally, the company's Vendor Code of Conduct expects vendors to minimize environmental impacts, reduce waste generation, and dispose of waste through safe and responsible methods.